[Comment] γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells

Multiple myeloma is a complex haematological malignancy characterised by the abnormal proliferation of plasma cells in the bone marrow. Despite notable advances in treatment options, treating individuals with relapsed or refractory multiple myeloma is still a challenge. With the advent of immune effector cell activating drugs, namely chimeric antigen receptor (CAR) T cells and bispecific antibodies, new therapeutic options have been used in this setting. B-cell maturation antigen (BCMA) was the first surface antigen targeted in individuals with multiple myeloma.